HDAC9 and colorectal carcinoma: To assess the capability of each HDAC subtype in upregulating CD47 expression, we treated CRC cells with inhibitors for type I HDAC (entinostat), type IIa HDAC (TMP269), type IIb HDAC (ricolinostat), type III HDAC (nicotinamide), or type IV HDAC (SIS17).